CVS Health Corporation $CVS Shares Purchased by Callahan Advisors LLC

Callahan Advisors LLC boosted its holdings in CVS Health Corporation (NYSE:CVS) by 15.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 88,808 shares of the pharmacy operator’s stock after buying an additional 12,158 shares during the period. Callahan Advisors LLC’s holdings in CVS Health were worth $6,695,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. increased its position in CVS Health by 1.7% during the second quarter. Vanguard Group Inc. now owns 120,399,131 shares of the pharmacy operator’s stock worth $8,305,132,000 after purchasing an additional 2,063,737 shares during the last quarter. State Street Corp grew its stake in shares of CVS Health by 1.4% during the 2nd quarter. State Street Corp now owns 58,788,585 shares of the pharmacy operator’s stock valued at $4,055,237,000 after buying an additional 800,414 shares during the period. Geode Capital Management LLC increased its holdings in shares of CVS Health by 2.4% during the 2nd quarter. Geode Capital Management LLC now owns 28,635,233 shares of the pharmacy operator’s stock worth $1,966,083,000 after buying an additional 675,824 shares during the last quarter. Invesco Ltd. raised its position in shares of CVS Health by 15.3% in the 2nd quarter. Invesco Ltd. now owns 23,532,479 shares of the pharmacy operator’s stock worth $1,623,270,000 after buying an additional 3,118,626 shares during the period. Finally, Norges Bank purchased a new position in shares of CVS Health in the 2nd quarter worth $1,358,698,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Stock Performance

CVS Health stock opened at $83.02 on Monday. CVS Health Corporation has a 12-month low of $53.28 and a 12-month high of $85.15. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.83 and a quick ratio of 0.63. The company has a market capitalization of $105.39 billion, a price-to-earnings ratio of 218.49, a price-to-earnings-growth ratio of 0.76 and a beta of 0.48. The firm’s fifty day moving average price is $79.05 and its 200 day moving average price is $74.84.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share for the quarter, beating the consensus estimate of $1.36 by $0.24. CVS Health had a return on equity of 11.45% and a net margin of 0.12%.The company had revenue of $102.87 billion during the quarter, compared to the consensus estimate of $98.85 billion. During the same period last year, the firm earned $1.09 earnings per share. The company’s revenue was up 7.8% on a year-over-year basis. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. On average, research analysts forecast that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Thursday, January 22nd will be paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 3.2%. The ex-dividend date is Thursday, January 22nd. CVS Health’s dividend payout ratio is 700.00%.

Analyst Upgrades and Downgrades

CVS has been the topic of a number of research reports. Wall Street Zen downgraded CVS Health from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. JPMorgan Chase & Co. raised their price target on shares of CVS Health from $93.00 to $101.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. Wells Fargo & Company decreased their price objective on shares of CVS Health from $103.00 to $102.00 and set an “overweight” rating for the company in a research note on Thursday, November 13th. Royal Bank Of Canada reissued an “outperform” rating on shares of CVS Health in a research note on Thursday, December 4th. Finally, Truist Financial set a $100.00 target price on shares of CVS Health in a report on Wednesday, December 10th. Nineteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $94.86.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS is activating pharmacies and advising patients to pick up prescriptions ahead of a major winter storm — shows operational readiness and continuity of care that can limit service disruption and protect short‑term revenue. Read More.
• Positive Sentiment: CVS announced programs aimed at making health insurance “simpler and more affordable,” signaling potential member growth and pricing or mix improvements for its health-insurance businesses. Read More.
• Positive Sentiment: Operational/PBM changes: CVS said it will cut some prior‑authorization requirements and expand rebate‑sharing — moves that could reduce friction for care delivery, improve customer experience and blunt policy/competitive criticisms. Read More.
• Positive Sentiment: Strategic/innovation: CVS is partnering with the University of Maryland on AI and pharmacy workforce development — a long‑term positive for efficiency and talent pipeline in its retail and clinical operations. Read More.
• Positive Sentiment: Market positioning: Reports show heavy buying of CVS call options, indicating some investors are positioned for further upside in the near term. Read More.
• Neutral Sentiment: Legal outcome: A Bloomberg Law piece says CVS and UnitedHealth successfully defended against an antitrust suit over drug costs — a favorable legal development but not necessarily dispositive for broader PBM scrutiny. Read More.
• Negative Sentiment: House Judiciary Committee report accuses CVS/Caremark of thwarting competition and targeting independent pharmacies — the committee alleges anticompetitive PBM practices, escalating regulatory and litigation risk that could pressure margins and valuation. Read More.
• Negative Sentiment: Follow‑up coverage: Multiple outlets (Becker’s, Seeking Alpha, MSN) detail the committee’s findings and show CVS executives were scrutinized in hearings over high costs and PBM conduct — these stories amplify political and regulatory uncertainty that investors price as risk. Read More. Read More. Read More.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.